JOURNAL OF CLINICAL MICROBIOLOGY, published by the American Society for Microbiology, stands as a premier resource for researchers and professionals in the field of medical microbiology. With an illustrious history dating back to 1975, this journal has consistently provided high-impact research, reflecting its status in the Q1 category among microbiology (medical) journals, and an impressive Scopus rank of 14 out of 140, placing it in the 90th percentile. The journal's commitment to unveiling foundational and innovative studies greatly contributes to understanding human health challenges posed by microbial pathogens. Researchers can expect rigorous peer-reviewed articles that cover a spectrum of topics, from diagnostic methods to clinical epidemiology, fostering a deeper understanding of microbiology's role in healthcare. While this journal does not offer open access options, its substantial impact factor underscores its relevance in shaping the conversation in clinical microbiology. The JOURNAL OF CLINICAL MICROBIOLOGY is indispensable for anyone dedicated to advancing their knowledge and practical skills in microbiology.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

The Japanese Journal of Infectious Diseases, published by the National Institute of Infectious Diseases in Japan, serves as a vital platform for researchers, clinicians, and public health professionals committed to advancing the field of infectious disease science. With an ISSN of 1344-6304 and an E-ISSN of 1884-2836, this journal has maintained its academic rigor since its inception in 1961 and continues to contribute significantly to the global understanding of infectious diseases. The journal holds a Q3 ranking in the categories of Infectious Diseases, Miscellaneous Medicine, and Medical Microbiology as of 2023, reflecting its important role in disseminating impactful research. With many articles available through Open Access, it ensures wide accessibility to the latest discoveries and insights. Researchers can expect to find high-quality studies that address critical challenges in the control and prevention of infectious diseases, making this journal an essential resource for anyone engaging in this critical field.

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

Archives of Clinical Infectious Diseases is a peer-reviewed journal dedicated to advancing knowledge in the field of infectious diseases, published by BRIEFLAND in Iran. With a broad scope, it covers various aspects of cardiology, critical care, immunology, microbiology, public health, and toxicology, affirming its relevance in today's health landscape. Despite the lack of open access options, the journal maintains a strong reputation, reflected in its Q3 ranking in multiple categories within the 2023 category quartiles. The journal aims to provide a platform for researchers and practitioners to disseminate critical findings that can impact clinical practices and public health policies. Its commitment to rigorous peer review ensures that only high-quality research is published, thereby serving as an essential resource for professionals, students, and public health advocates. For those engaged in the ever-evolving world of infectious diseases, Archives of Clinical Infectious Diseases stands as a vital contribution to the medical literature.

MIKROBIYOLOJI BULTENI, with ISSN 0374-9096, is a prestigious academic journal published by the ANKARA MICROBIOLOGY SOC, located in Ankara, Turkey. Established in 1973, this journal has been a vital conduit for disseminating research in the fields of Immunology, Microbiology, and Infectious Diseases, garnering a reputation as a significant contributor to the scientific community. The journal is currently ranked in the Q3 category within Immunology and Microbiology (miscellaneous), and Infectious Diseases, indicating its impactful presence amidst contemporary research. With access options that may be restricted, MIKROBIYOLOJI BULTENI actively welcomes submissions that advance the understanding of critical microbiological principles and practices, thereby supporting both national and international research efforts. Researchers, professionals, and students are encouraged to explore the latest findings shared in this journal, as it continually shapes the landscape of microbiology and infectious disease studies through its comprehensive and rigorous peer-reviewed publications.

Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.

International Journal of Mycobacteriology is a peer-reviewed, open-access journal published by Wolters Kluwer Medknow Publications that specializes in the field of infectious diseases with a particular emphasis on mycobacterial research. Since its inception in 2012, this journal has emerged as a vital resource for researchers, healthcare professionals, and students aimed at advancing understanding and treatment of mycobacterial infections, including tuberculosis. With the journal being indexed in Scopus and holding a Q3 ranking in both Infectious Diseases and Microbiology (medical) for 2023, it reflects a substantial contribution to scholarly discourse in these domains, despite its current ranking positioning. Authors and readers benefit from the open access model, ensuring widespread dissemination of research findings and fostering collaboration across the global health community. Located in Mumbai, India, the journal continues to thrive with a commitment to quality research and innovation, welcoming contributions that further the exploration of mycobacteriology throughout the converged years from 2012 to 2024.